drugset / Trial / NCT06495918
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
Phase 3
Active not recruiting
825 enrolled
Ocular Therapeutix, Inc.
Duke University · collabFortrea · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration
Timeline
- Start
- 2024-11-27
- Primary completion
- 2027-01-08
- Completion
- 2027-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | Aflibercept | Protein / enzyme biologic | 8 mg | Intravitreal |
| Subject | Axitinib | Small molecule | — | Intravitreal |